The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.
Avinash Gupta
No relevant relationships to disclose
Sharon Love
No relevant relationships to disclose
Anna Schuh
Honoraria - Celgene; GlaxoSmithKline; Mundipharma; Roche
Linda Collins
No relevant relationships to disclose
Adelyn Thomason
No relevant relationships to disclose
Ruth Asher
No relevant relationships to disclose
Richard Lisle
No relevant relationships to disclose
Michael Churchman
No relevant relationships to disclose
Milensu Shanyinde
No relevant relationships to disclose
Ruth Plummer
Research Funding - AstraZeneca
Paul D. Nathan
No relevant relationships to disclose
Sarah Danson
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - AstraZeneca
Christian H.H Ottensmeier
No relevant relationships to disclose
Paul Lorigan
Research Funding - AstraZeneca
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer
Mark R. Middleton
Consultant or Advisory Role - AstraZeneca